ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
Home » ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform2021-09-142021-09-16http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.